Development
Thermo Fisher Scientific Inc.
TMO
$415.15
$0.610.15%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 2.95% | -1.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.95% | -1.06% | |||
| Cost of Revenue | 3.79% | -2.74% | |||
| Gross Profit | 1.74% | 1.48% | |||
| SG&A Expenses | -0.78% | -4.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.67% | -3.34% | |||
| Operating Income | 4.21% | 10.49% | |||
| Income Before Tax | -0.51% | 23.62% | |||
| Income Tax Expenses | 150.94% | 1.92% | |||
| Earnings from Continuing Operations | -5.25% | 24.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 20.00% | 2,100.00% | |||
| Net Income | -4.96% | 26.01% | |||
| EBIT | 4.21% | 10.49% | |||
| EBITDA | 2.43% | 6.99% | |||
| EPS Basic | -5.20% | 26.01% | |||
| Normalized Basic EPS | 5.58% | 15.99% | |||
| EPS Diluted | -4.98% | 25.93% | |||
| Normalized Diluted EPS | 5.85% | 15.99% | |||
| Average Basic Shares Outstanding | 0.26% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 0.06% | -0.21% | |||